447 related articles for article (PubMed ID: 20939065)
41. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in
Xiao Z; Liu J; Liu SH; Petridis L; Cai C; Cao L; Wang G; Chin AL; Cleveland JW; Ikedionwu MO; Carrick JD; Smith JC; Quarles LD
Mol Pharmacol; 2021 Jun; 101(6):408-421. PubMed ID: 35339985
[TBL] [Abstract][Full Text] [Related]
42. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
43. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.
Shimada T; Urakawa I; Yamazaki Y; Hasegawa H; Hino R; Yoneya T; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Biochem Biophys Res Commun; 2004 Feb; 314(2):409-14. PubMed ID: 14733920
[TBL] [Abstract][Full Text] [Related]
44. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.
Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB
J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835
[TBL] [Abstract][Full Text] [Related]
45. Comparison of two assays for fibroblast growth factor (FGF)-23.
Ito N; Fukumoto S; Takeuchi Y; Yasuda T; Hasegawa Y; Takemoto F; Tajima T; Dobashi K; Yamazaki Y; Yamashita T; Fujita T
J Bone Miner Metab; 2005; 23(6):435-40. PubMed ID: 16261449
[TBL] [Abstract][Full Text] [Related]
46. Increased Col10a1 expression is not causative for the phenotype of Phex-deficient Hyp mice.
Yorgan T; Rendenbach C; Jeschke A; Amling M; Cheah KS; Schinke T
Biochem Biophys Res Commun; 2013 Dec; 442(3-4):209-13. PubMed ID: 24269824
[TBL] [Abstract][Full Text] [Related]
47. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
Perwad F; Portale AA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1097-1099. PubMed ID: 31171590
[No Abstract] [Full Text] [Related]
48. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
49. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
Takashi Y; Kawanami D; Fukumoto S
Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
[TBL] [Abstract][Full Text] [Related]
50. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
51. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice.
Mohamed FF; Hoac B; Phanrungsuwan A; Tan MH; Giovani PA; Ghiba S; Murshed M; Foster BL; McKee MD
Bone; 2023 Nov; 176():116886. PubMed ID: 37634682
[TBL] [Abstract][Full Text] [Related]
52. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Fukumoto S; Yamashita T
Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):385-9. PubMed ID: 12105387
[TBL] [Abstract][Full Text] [Related]
53. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice Partially Rescues the Deficient Mineralization Without Correcting Hypophosphatemia.
Hoac B; Østergaard M; Wittig NK; Boukpessi T; Buss DJ; Chaussain C; Birkedal H; Murshed M; McKee MD
J Bone Miner Res; 2020 Oct; 35(10):2032-2048. PubMed ID: 32501585
[TBL] [Abstract][Full Text] [Related]
54. The muscle-bone relationship in X-linked hypophosphatemic rickets.
Veilleux LN; Cheung MS; Glorieux FH; Rauch F
J Clin Endocrinol Metab; 2013 May; 98(5):E990-5. PubMed ID: 23526465
[TBL] [Abstract][Full Text] [Related]
55. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.
Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM
J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863
[TBL] [Abstract][Full Text] [Related]
56. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.
Brownstein CA; Zhang J; Stillman A; Ellis B; Troiano N; Adams DJ; Gundberg CM; Lifton RP; Carpenter TO
Endocrinology; 2010 Feb; 151(2):492-501. PubMed ID: 19952276
[TBL] [Abstract][Full Text] [Related]
57. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
[TBL] [Abstract][Full Text] [Related]
58. Bone Volumetric Density, Microarchitecture, and Estimated Bone Strength in Tumor-Induced Rickets/Osteomalacia
Jiajue R; Ni X; Jin C; Yu W; Huo L; Wu H; Liu Y; Jin J; Lv W; Zhou L; Xia Y; Chi Y; Cui L; Pang Q; Li X; Jiang Y; Wang O; Li M; Xing X; Meng X; Xia W
Front Endocrinol (Lausanne); 2022; 13():883981. PubMed ID: 35769089
[TBL] [Abstract][Full Text] [Related]
59. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
60. Vitamin D supplementation improves bone mineralisation independent of dietary phosphate in male X-linked hypophosphatemic (Hyp) mice.
Barratt KR; Sawyer RK; Atkins GJ; St-Arnaud R; Anderson PH
Bone; 2021 Feb; 143():115767. PubMed ID: 33232838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
